CAMK2G and atrial fibrillation: Compared with the control group, the ibrutinib group displayed Ca2+ dysregulation in atrial myocytes, it increased spontaneous Ca2+ release, CaMKII level, phosphorylated CaMKII, and other related sites, and reduced sarcoplasmic Ca2+ capacity (41); both may lead to AF.